Investors

Press Releases

 
Press Releases
  Date Title View
Apr 6, 2016
WATERTOWN, Mass., April 06, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the 15th Annual Needham & Co. Hea...
Mar 10, 2016
WATERTOWN, Mass., March 10, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the 28th Annual Roth Conference o...
Feb 23, 2016
WATERTOWN, Mass., Feb. 23, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the fourth quarter and year ended December 31, 2015 and provided a review o...
Feb 19, 2016
WATERTOWN, Mass., Feb. 19, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will report fourth quarter and full year financial results after the clo...
Jan 19, 2016
WATERTOWN, Mass., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced the initiation of patient dosing in a phase 1 clinical trial for intravenous (IV) TP-271, a novel, broad-spectrum antibiotic candidate which is being developed to combat respiratory disease caused by bacterial biothreats and antibiot...
Dec 3, 2015
WATERTOWN, Mass., Dec. 3, 2015 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that Guy Macdonald, Tetraphase's President and Chief Executive Officer, will present at the Oppenhe...
Nov 12, 2015
WATERTOWN, Mass., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation, including an update on its eravacyclin...
Nov 2, 2015
WATERTOWN, Mass., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the quarter ended September 30, 2015. "Despite the recent setback with...
Oct 7, 2015
WATERTOWN, Mass., Oct. 7, 2015 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, announced today that two posters will be presented at IDWeek 2015 on the company's lead antibiotic candidate, erava...
Sep 8, 2015
Eravacycline Did Not Achieve Primary Endpoint in Pivotal Portion of cUTI Trial Company to Host Conference Call at 4:30 p.m. ET Today WATERTOWN, Mass., Sept. 8, 2015 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening mu...
FirstPrevious
3
...
NextLast
= add release to Briefcase